A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma

BACKGROUND: The alpha v beta 3 (αvβ3) integrin is involved in intracellular signaling regulating cell proliferation, migration, and differentiation and is important for tumor‐induced angiogenesis. METHODS: This phase 2, randomized, open‐label, 2‐arm study was designed to capture safety data and eval...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer 2010-03, Vol.116 (6), p.1526-1534
Hauptverfasser:	Hersey, Peter, Sosman, Jeffrey, O'Day, Steven, Richards, Jon, Bedikian, Agop, Gonzalez, Rene, Sharfman, William, Weber, Robert, Logan, Theodore, Buzoianu, Manuela, Hammershaimb, Luz, Kirkwood, John M.
Format:	Artikel
Sprache:	eng
Schlagworte:	alpha v beta 3 Biological and medical sciences clinical trials Dermatology etaracizumab (Abegrin) Medical sciences melanoma Tumors Tumors of the skin and soft tissue. Premalignant lesions
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!